Cite

HARVARD Citation

    Lewis-Wolfson, T. et al. (n.d.). 409: BARICITINIB VERSUS TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19. Critical care medicine. p. 191. [Online]. 
  
Back to record